Plasma Pyrophosphate Imbalance According to Phenotype and Bone Remodelling Alterations in Type 1 Neurofibromatosis - PIRATE-NF1 - (PIRATE)

November 16, 2026 updated by: University Hospital, Angers

Neurofibromatosis type 1 (NF1) is a multisystemic genetic disorder associated with frequent tumor, skin, visceral, and bone manifestations. Plexiform neurofibromas (PFNs), whether superficial or deep, affect 20 to 50 percent of patients and are responsible for significant morbidity. Inoperable, symptomatic PFNs can now be treated with targeted therapy (selumetinib) in both children and adults. Furthermore, NF1 patients frequently present with bone abnormalities, such as bone dysplasia, scoliosis, or reduced bone mineral density, suggesting impaired mineralization.

Inorganic pyrophosphate (PPi) is a potent antagonist of bone mineralization. It has been shown in a mouse model of NF1 and in human Schwann cell cultures derived from patients with NF1 (2 cases) that there is activation of genes regulating PPi homeostasis, particularly ANKH and ENPP1.

This study aims to measure plasma PPi levels in a cohort of patients with NF1 from the general population, based on their phenotype-specifically, the presence, location, and characteristics of NFPs-as well as their calcium and phosphorus levels.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 100 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

40 patients. Age ≥18 years ; Confirmed diagnosis of NF1, based on current clinical and/or molecular criteria.

Description

Inclusion Criteria:

  • Age ≥18 years
  • Confirmed diagnosis of NF1, based on current clinical and/or molecular criteria
  • Consent obtained

Exclusion Criteria:

  • Other condition affecting bone mineralization
  • Known severe renal insufficiency
  • Patient who refuses to participate in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Diagnosed patients with NF1

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
PPi plasma concentration.
Time Frame: Visite 1
Visite 1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plasma PPI Levels in NF1 patients
Time Frame: At the time of the consultation
At the time of the consultation
Urine PPI Levels in NF1 patients
Time Frame: At the time of the consultation
At the time of the consultation
presence of a plexiform neurofibroma in NF1 patients
Time Frame: At the time of the consultation
At the time of the consultation
presence of bone abnormalities in NF1 patients
Time Frame: At the time of the consultation
At the time of the consultation
Urinary PPI measurement in newly diagnosed patients with NF1
Time Frame: At the time of the consultation
At the time of the consultation
Location of plexiform neurofibromas
Time Frame: At the time of the consultation
At the time of the consultation
Calcium measurement
Time Frame: At the time of the consultation

Biological parameters of calcium-phosphorus metabolism (calcium, phosphorus, vitamin D, and PTH)

At the time of the consultation
Phosporus measurement
Time Frame: At the time of the consultation

Biological parameters of calcium-phosphorus metabolism (calcium, phosphorus, vitamin D, and PTH)

At the time of the consultation
Vitamine D Assay
Time Frame: At the time of the consultation

Biological parameters of calcium-phosphorus metabolism (calcium, phosphorus, vitamin D, and PTH)

At the time of the consultation
Parathyroid hormone (PTH) measurement
Time Frame: At the time of the consultation

Biological parameters of calcium-phosphorus metabolism (calcium, phosphorus, vitamin D, and PTH)

At the time of the consultation
Treatment with selumetinib
Time Frame: Visite 1
Visite 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Pauline BOITEZ, MD, University Hospital, Angers

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 9, 2027

Primary Completion (Estimated)

June 23, 2028

Study Completion (Estimated)

July 21, 2028

Study Registration Dates

First Submitted

November 3, 2026

First Submitted That Met QC Criteria

November 16, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.